Affordable Access

deepdyve-link
Publisher Website

Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.

Authors
  • Beal, Eliza W1
  • Ahmed, Ahmed1
  • Grotz, Travis2
  • Leiting, Jennifer2
  • Fournier, Keith F3
  • Lee, Andrew J3
  • Dineen, Sean4
  • Dessureault, Sophie4
  • Baumgartner, Joel M5
  • Veerapong, Jula5
  • Clarke, Callisia6
  • Strong, Erin6
  • Maithel, Shishir K7
  • Zaidi, Mohammad Y7
  • Patel, Sameer8
  • Dhar, Vikrom8
  • Hendrix, Ryan9
  • Lambert, Laura9
  • Johnston, Fabian10
  • Fackche, Nadege10
  • And 7 more
  • 1 The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, USA.
  • 2 Mayo Clinic, Rochester, MN, USA.
  • 3 MD Anderson Cancer Center, Houston, TX, USA.
  • 4 Moffitt Cancer Center, Tampa, FL, USA.
  • 5 University of California San Diego, San Diego, CA, USA.
  • 6 Medical College of Wisconsin, Milkwaukee, WI, USA.
  • 7 Emory University, Atlanta, GA, USA.
  • 8 University of Cincinnati, Cincinnati, OH, USA.
  • 9 University of Massachusetts Memorial Medical Center, Worcester, MA, USA.
  • 10 Johns Hopkins University, Baltimore, MD, USA.
  • 11 City of Hope, Duarte, CA, USA.
  • 12 University of Wisconsin, Madison, WI, USA.
  • 13 The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus, OH, USA. Electronic address: [email protected] , (Jordan)
Type
Published Article
Journal
American journal of surgery
Publication Date
Mar 01, 2020
Volume
219
Issue
3
Pages
478–483
Identifiers
DOI: 10.1016/j.amjsurg.2019.09.017
PMID: 31558307
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an increasingly utilized strategy for patients with peritoneal surface malignancies (PSM). The US HIPEC Collaborative was retrospectively reviewed to compare the indications and perioperative outcomes of patients who underwent CRS ± HIPEC between 2000 and 2012 (P1) versus 2013-2017 (P2). Among 2,364 patients, 39% were from P1 and 61% from P2. The most common primary site was appendiceal (64%) while the median PCI was 13 and most patients had CCR 0 (60%) or 1 (25%). Over time, median estimated blood loss, need for transfusion, and length of hospital stay decreased. While the incidence of any (55% vs. 57%; p = 0.426) and Clavien III/IV complications did not change over time, there was a decrease in 90-day mortality (5% vs. 3%; p = 0.045). CRS-HIPEC is increasingly performed for PSM at high-volume centers. Despite improvements in some perioperative outcomes and a reduction in postoperative mortality, morbidity rates remain high. Copyright © 2019 Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times